# US 2020/0347094 A1 · Preparation Method of Activated or Solubilized Mutated Enzyme

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347094 A1
- Document ID: US20200347094A1
- Status: Published application
- Kind: A1
- Application number: 16/877,789
- Filed: 2020-05-19
- Published: 2020-11-05
- Earliest claimed: 2015-06-10
- Assignees: Toyama Prefectural University
- Applicants: Toyama Prefectural University
- Inventors: Yasuhisa Asano; Daisuke Matsui; Yuko Oku
- Web page: https://patentgrep.com/patent/US20200347094A1

## CPC

- C07K 4/12: from animals; from humans
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- C12N 9/00: Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
- C12N 9/0016: {with NAD or NADP as acceptor (1.4.1)}
- C12N 9/0069: {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- C12N 9/88: Lyases (4.)
- C12N 15/01: Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- C12N 15/09: Recombinant DNA-technology
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12Y 401/01017: Ornithine decarboxylase (4.1.1.17)
- C12Y 401/01019: Arginine decarboxylase (4.1.1.19)
- C12Y 101/03: with a oxygen as acceptor (1.1.3)
- C12Y 104/01002: Glutamate dehydrogenase (1.4.1.2)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method for producing an active-form mutant enzyme, by specifying a protein of which a native form exhibits an enzyme activity but which has 10% or less enzyme activity of the native form when a gene of the protein is expressed to provide an inactive-form enzyme; determining a sequence conservation of amino acid residues in an amino acid sequence of the inactive-form enzyme and specifying amino acid residue(s) for which sequence conservation in the inactive-form enzyme is lower than sequence conservation of other amino acid(s) of the same residue; preparing a gene having a base sequence that codes for the amino acid sequence of the inactive-form enzyme in which at least one said specified amino acid residue is substituted by another amino acid with a higher sequence conservation; and expressing the gene to obtain an enzyme that exhibits an enzyme activity of the native form protein.

## Claims

### Claim 1

A method for producing an active-form mutant enzyme, comprising steps of:
(1) specifying a protein of which a native form of the protein exhibits an enzyme activity but which exhibits no enzyme activity or 10% or less enzyme activity of the enzyme activity exhibited by the protein in the native form when a gene of the protein is expressed in a heterologous expression system to provide an inactive-form enzyme;
(2b) determining a sequence conservation in sequence identity of at least some amino acid residues in an amino acid sequence of the inactive-form enzyme provided in step (1) and among said amino acid residues, specifying at least one amino acid residue for which sequence conservation of the amino acid in the inactive-form enzyme is lower than sequence conservation of one or more other amino acids of the same residue;
(3b) preparing a gene having a base sequence that codes for an amino acid sequence which is the amino acid sequence of the inactive-form enzyme provided in step (1) in which at least one said amino acid residue specified in step (2b) is substituted by another amino acid of the same residue with a higher sequence conservation than said substituted amino acid; and
(4b) expressing, in a heterologous expression system, the gene having the base sequence prepared in step (3b) to obtain a protein that exhibits a same sort of enzyme activity as the native form of the protein to provide an active form mutant enzyme.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the amino acid sequence for which the sequence conservation in sequence identity is determined in step (2b) is selected from an amino acid sequence of an α-helix structure region of the inactive-form enzyme provided in step (1).

### Claim 3 (depends on 1)

The method according to claim 1, wherein three amino acid residues in which sequence conservation of the amino acid in the inactive-form enzyme is lower than sequence conservation of one or more other amino acids of the same residue are specified in step (2b) and in step 3(b) each of the three amino acid residues specified in step (2b) is substituted, respectively, by another amino acid of the same residue as the substituted amino acid that has a higher conservation than said substituted amino acid.

### Claim 4 (depends on 1)

The method according to claim 1, wherein in said step (3b), the amino acid substitution is carried out for a plurality of said amino acid residues specified in step (2b) and in said step (4b), the active-form mutant enzyme that is obtained is a protein in which a plurality of said amino acid residues specified in step (2b) have been substituted.

### Claim 5 (depends on 4)

The method according to claim 4, wherein sequence conservations of at least two different amino acid sequences of the inactive-form enzyme provided in step (1) are determined in step (2b) and in step 3(b) at least one amino acid residue of each of said at least two different sequences is substituted. respectively, by another amino acid of the same residue as the substituted amino acid that has a higher conservation than said substituted amino acid.

### Claim 6 (depends on 1)

The producing method according to claim 1, wherein sequence conservation was calculated on INTMSAlign by a method comprising by steps of:
(i) obtaining BLAST search results by
a) entering the sequence of one or more of α-helix structure regions of the inactive-form enzyme on the BLAST site,
b) selecting 5000 as a maximum number of target sequences,
ci) using 1.0E−3 as Expect threshold, and
(ii) comparing protein sequences obtained from the BLAST search results using the INTMSAlign.

### Claim 7

A method for producing a soluble mutant protein, comprising steps of:
(1) specifying a protein of which a native form is a soluble protein but which protein is insoluble when a gene of the protein is expressed in a heterologous expression system to provide an insoluble-form protein;
(2b) determining a sequence conservation in sequence identity of at least some amino acid residues in an amino acid sequence of the insoluble-form protein provided in step (1) and among said amino acid residues, specifying at least one amino acid residue in which sequence conservation of the amino acid in the insoluble-form protein is lower than sequence conservation of one or more other amino acids of the same residue;
(3b) preparing a gene having a base sequence that codes for an amino acid sequence which the amino acid sequence of the insoluble-form protein provided in step (1) in which at least one said amino acid specified in step (2b) is substituted with another amino acid of the same amino acid residue with a higher sequence conservation than said substituted amino acid; and
(4b) expressing, in a heterologous expression system, the gene having the base sequence prepared in step (3b) to provide a soluble mutant protein.

### Claim 8 (depends on 7)

The method according to claim 7, wherein solubility of the soluble mutant protein is determined based on an amount of the soluble protein in an extract after heterologous expression in step (4b).

### Claim 9 (depends on 8)

The method according to claim 8, wherein the soluble mutant protein is defined as a mutant protein for which the amount of the soluble protein in the extract after heterologous expression in step (4b) is higher than an amount of soluble protein in the same extract after heterologous expression of the native form protein.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the amino acid sequence for which the sequence conservation in sequence identity is determined in step (2b) is selected from an amino acid sequence of an α-helix structure region of the insoluble-form protein provided in step (1).

### Claim 11 (depends on 7)

The method according to claim 7, wherein three amino acid residues in which sequence conservation of the amino acid in the inactive-form enzyme is lower than sequence conservation of one or more other amino acids of the same residue are specified in step (2b) and in step 3(b) each of the three amino acid residues specified in step (2b) is substituted, respectively, by another amino acid of the same residue as the substituted amino acid that has a higher conservation than said substituted amino acid.

### Claim 12 (depends on 7)

The method according to claim 7, wherein in said step (3b), the amino acid substitution is carried out for a plurality of said amino acid residues specified in step (2b) and in said step (4b), the soluble mutant protein that is obtained is a protein in which a plurality of said amino acid residues specified in step (2b) have been substituted.

### Claim 13 (depends on 12)

The method according to claim 12, wherein sequence conservations of at least two different amino acid sequences of the insoluble-form protein provided in step (1) are determined in step (2b) and in step (3b) at least amino acid residue of each of said at least two different sequences is substituted. respectively, by another amino acid of the same residue as the substituted amino acid that has a higher conservation than said substituted amino acid.

### Claim 14 (depends on 7)

The method according to claim 7, wherein sequence conservation was calculated on INTMSAlign by a method comprising by steps of:
(i) obtaining BLAST search results by
a) entering the sequence of one or more of α-helix structure regions of the inactive-form enzyme on the BLAST site,
b) selecting 5000 as a maximum number of target sequences,
ci) using 1.0E−3 as Expect threshold, and
(ii) comparing protein sequences obtained from the BLAST search results using the INTMSAlign.
